Skip to main content

How can we help you?

  • Deal or case news
  • 14-08-2020

On 14 August 2020, CureVac NV launched a successful IPO on the Nasdag Global Market, raising USD 213 million. The company raised a further USD 118 million in a private placement and recently completed a USD 640 million private financing round. These three transactions collectively represent equity investments of more than USD one billion. NautaDutilh acted as Dutch counsel to CureVac for the private financing round, the IPO and the private placement, alongside Davis Polk & Wardwell (US counsel) and Rittershaus (German counsel).

CureVac is a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), including an mRNA vaccine for the novel coronavirus that causes Covid-19. 

NautaDutilh is proud to have been able to help CureVac reach this important milestone. 

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.